1	Comparison of the prevalence and associated factors of chronic kidney disease diagnosed by serum
2	creatinine or cystatin C among young people living with HIV in Uganda.
3	Esther M Nasuuna ^{1,2} , Laurie A Tomlinson ³ , Robert Kalyesubula ^{1,4} , Chido Dziva Chikwari ^{5,6} , Barbara
4	Castelnuovo ¹ , Yukari C Manabe ^{2,7} , Damalie Nakanjako ^{2,8} , Helen A. Weiss ⁶
5	
6	1 Non-communicable Diseases Program, Medical Research Council/Uganda Virus Research Institute
7	and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe Uganda
8	2 Infectious Diseases Institute, Makerere University, College of Health Sciences, Kampala, Uganda
9	3. Department of non-Communicable Disease Epidemiology, London School of Hygiene and Tropical
10	Medicine, Keppel Street, London, WC1E 7HT, UK
11	4. Departments of Physiology and Medicine, Makerere University College of Health Sciences, Kampala,
12	Uganda
13	5. Biomedical Research and Training Institute, Harare, Zimbabwe
14	6. MRC International Statistics and Epidemiology Group, London School of Hygiene & Tropical
15	Medicine, London, UK
16	7. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
17	8. Department of Medicine, School of Medicine, College of Health Sciences, Makerere University,
18	Kampala, Uganda
19	
20	Corresponding author

21 Esther Nasuuna

22 enasuuna@idi.co.ug

23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	Abstract
34	
35	Introduction
36	Young people living with HIV (YPLHIV) are at increased risk of developing chronic kidney disease
37	(CKD) which is associated with high mortality and morbidity. Early diagnosis is important to halt
38	progression. We aimed to estimate the prevalence and factors associated with CKD among YPLHIV in
39	Kampala, Uganda, and to compare serum creatinine and cystatin C for early diagnosis of CKD in this
40	population.
41	Methods
42	A cross-sectional study with YPLHIV aged 10 to 24 years was conducted in seven HIV clinics.
43	Participants provided a urine and blood sample to measure urinary albumin, proteinuria, serum creatinine

44	and cystatin C levels at baseline and after three months. The estimated glomerular filtration rate (eGFR)
45	was calculated using CKDEPI 2021, Cockroft-Gault and bedside Schwartz equations using creatinine or
46	cystatin C. The albumin creatinine ratio (ACR) and proteinuria were measured. CKD was defined as
47	either eGFR <60 ml/min/1.73m ² or <90 ml/min/1.73m ² or ACR above 30mg/g on two separate occasions.
48	Univariable and multivariable logistic regression were used to estimate adjusted odds ratios (aOR) and
49	95% confidence intervals (CI) for factors associated with CKD.
50	Results
51	A total of 500 participants were enrolled. Most were female (56%; n=280) and aged 10 to 17 years
52	(66.9%; n=335). CKD prevalence ranged from 0-23% depending on the criteria, equation and biomarker
53	used. Cystatin C-based equations estimated higher prevalence of CKD compared to creatinine-based ones.
54	Prevalence of ACR above 30mg/g was 10.1% and of proteinuria 29%. Factors independently associated
55	with CKD were age (aOR=1.42; 95% CI:1.30-1.51) and male sex (aOR=3.02; 95% CI:1.68-5.43).
56	Conclusion
57	CKD prevalence among YPLHIV varied substantially depending on definitions used and the current
58	definition would likely lead to missed cases of CKD among YPLHIV. Estimating equations should be
59	validated against measured GFR in YPLHIV and the optimal definition of CKD in this vulnerable
60	population should be revised to optimise detection and opportunities for reducing disease progression.
61	
62	Key words: prevalence, chronic kidney disease, young people, HIV, Africa, HIV comorbidities
63	
64	
65	Introduction
66	Prevalence of chronic kidney disease (CKD) is increasing globally (1). CKD is defined as abnormalities
67	in kidney structure or function present for three or more months (2). The Global Burden of Disease study

estimates CKD prevalence at 9.1% (95% CI 8.5%-9.8%) with geographic variation (3). Studies in SubSaharan Africa (SSA) find prevalence ranging from 6%-48% depending on the population, the definitions
used, and the measurements taken (4-6).
Young people living with HIV (YPLHIV) are at higher risk of CKD than young people not living with
HIV (7). CKD risk is associated with high HIV viremia (>4000 copies per ml), severe
immunosuppression (CD4 cell count <200 cells/ml), infection with hepatitis C virus, diabetes,
hypertension, use of drugs that treat opportunistic infections, and toxicity due to anti-retroviral therapy

75 (ART) from tenofovir disoproxil fumarate (TDF) and indinavir (6, 8-11). Further, YPLHIV in SSA are

76 particularly vulnerable to developing CKD compared to adults living with HIV due to late HIV diagnosis

and initiation on ART, poorer adherence to ART complicated by high viremia and low CD4 cell counts

78 (12-14).

79 CKD is associated with high morbidity and mortality as diagnosis is usually delayed, often occurring after

80 kidney failure due to its insidious onset (15). Kidney failure can only be treated with expensive kidney

81 replacement therapies that are not readily available in low and middle-income countries (16). Early

82 diagnosis is important to minimise risk of progression to kidney failure and cardiovascular events (17).

83 Diagnosis of CKD is based on the level of glomerular filtration rate (GFR) and markers of kidney damage

such as protein excretion into the urine shown by proteinuria or albuminuria (18). GFR can either be

85 measured directly (mGFR) or estimated (eGFR) with a specific biomarker and one of the estimating

86 equations (19). Most commonly, serum creatinine and cystatin C estimating equations are used to

estimate GFR (18, 20). Serum creatinine is widely available and relatively cheap (21) but has limitations

as it is influenced by muscle mass, physical activity and general health status (22) as well as high analytic

89 variability (21). Cystatin C is not affected by these conditions as it is produced by most nucleated cells

90 and has uniform generation despite individual differences in people and situations (22-24). However, it is

91 affected by conditions of high inflammation, corticosteroid use and thyroid disease (25). Cystatin C more

4

92 accurately estimated measured GFR compared to creatinine (26) in a large cohort study done across

93 Uganda, Malawi and South Africa that recommended the use of Cystatin C in African populations (4).

Although YPLHIV are at high risk of CKD, little is known about CKD prevalence, the best biomarker to
diagnose CKD and factors associated with CKD in this vulnerable group. Therefore, we sought to study
this among YPLHIV in Kampala, Uganda.

97 Methods

98 Study design and setting: This cross-sectional study was conducted in the HIV clinics of seven urban public health facilities from the 12th of April 2023 to 31st January 2024 in Kampala, Uganda, These offer 99 100 comprehensive HIV care to children (aged below 18 years) and adults (aged 18 years and above). 101 **Study population and sampling:** The study included YPLHIV aged 10-24 years with presumed perinatal 102 HIV infection (defined as being diagnosed with HIV before 10 years of age with self-report of no sexual 103 debut or blood transfusion prior to diagnosis). Pregnant YPLHIV were excluded. Systematic random 104 sampling was used to identify potential participants from all YPLHIV enrolled in the seven HIV clinics 105 from electronic medical records. They were ordered by age at diagnosis and every third person invited to 106 join the study. A sample size of 500 was powered to detect a prevalence of CKD between 16% and 24%. 107 Study procedures: Eligible participants were invited to the HIV clinic through a phone call where they 108 were screened, consented, and enrolled. A trained study team member conducted an interview with the 109 participant and completed a questionnaire to record demographic information, symptoms, risk factors and 110 the relevant medical history. Anthropometric measurements (mid-upper arm circumference (MUAC), 111 weight and height) were taken. Weight was assessed using a digital weighing scale, height using a 112 stadiometer and blood pressure (BP) using a digital BP machine with a paediatric cuff for younger 113 participants. Body composition monitoring was conducted using bioimpedance impedance spectroscopy 114 (BIS) to measure body fat, muscle mass and visceral fat. Participants provided a spot urine sample (20 115 mls) as well as 8 ml of venous blood. Urine dipstick was done at the facility to determine proteinuria and

116 other urinary abnormalities. The samples were stored in a cooler box before transfer to the study

laboratory on the same day. 117 118 Laboratory methods and testing: In the laboratory, serum creatinine, urinary albumin and cystatin C 119 levels were determined. Those with an albumin creatinine ratio (ACR) >30mg/g or eGFR <60ml/min/1.73m² at baseline were followed-up after three months to confirm the KDIGO guideline-120 121 recommended clinical diagnosis of CKD. Cystatin C was measured by particle-enhanced 122 immunoturbidimetric assay on Roche Cobas C311 platform with Tina-quant Cystatin C Gen.2. Creatinine 123 was measured using the enzymatic calorimetric method using an isotope dilution mass spectroscopy 124 (IDMS) traceable standard reference material on the Cobas Integra 400 plus machine with Creatinine Plus 125 Version 2 (CREP2), Roche Diagnostics. The urine albumin was quantified using the 126 immunoturbidimetric assay on the Roche Cobas C311 platform using Tina quant Albumin Gen2, (Roche 127 Diagnostics). Prior to testing, the machines were calibrated according to manufacturer instructions. 128 Urinalysis by dipstick was done with AYDMED urinalysis Reagent Test Strips (Sungo Europe B.V 129 Amsterdam) to determine presence of urobilinogen, bilirubin, ketones, blood, proteins, nitrites, leucocytes, glucose, specific gravity, pH, and ascorbic acid (27). 130 131 **Diagnosis of CKD** was based on the kidney disease improving global outcomes (KDIGO) guidelines 132 (28), i.e. 1) markers of kidney damage such as an albumin: creatinine ratio >30mg/g, or 2) eGFR 133 <60ml/min/1.73m², with these abnormalities confirmed with a repeat test after three months (29). To 134 explore CKD definition in this cohort that included children and where chronic disease had affected 135 pubertal development and mean body and muscle mass, we primarily used a range of GFR estimating 136 equations and eGFR cut offs that reflected contemporary practice for adults and children and/or sought to 137 adjust for body size. eGFRscr was estimated using the following creatinine-based equations: CKD 138 Epidemiology collaboration (CKDEPI) 2021 (30), the Bedside Schwartz (31), and Cockroft-Gault. 139 eGFRcystc was estimated using the following cystatin C-based equations: Schwartz cystatin C (32) and 140 CKDEPI 2012 (33). For completeness prevalence was also estimated using other relevant equations (Full 141 Age Spectrum, CKDEPI40 and Pierce U25), and in combination with ACR and proteinuria. Since a

normal GFR is between 90-120 ml/min/1.73m², we also considered a eGFR cut off below

143 90 ml/min/1.73m² which is considered stage 2 CKD as abnormal in such a young population (34).

144 Data management and statistical analysis: Data were collected in REDCap and analysed with STATA 145 statistical software version 18 (STATA Corp USA). Viral suppression was considered as an HIV viral 146 load below 1000 copies/ml. Hypertension was classified according to the AAP guidelines as being above the 95th percentile for age and sex below 13 years and above 130/80 in those above 13 years (35). Muscle 147 148 mass was abnormal if below 33.3 for males and 24.3 for females. Social economic status was divided into 149 three using principal component analysis. Demographic data were summarised in percentages or means 150 (standard deviation) and median (interquartile range). The distribution of eGFRs estimated with different 151 equations was shown in a Kernel density plot. CKD prevalence diagnosed by either creatinine or cystatin 152 C was calculated. Univariable logistic regression was used to estimate odds ratios (OR) of factors 153 associated with CKD for each of the five equations used, respectively. All variables with p < 0.2 in the 154 univariable model, and a-priori identified variables known to be associated with CKD (age, sex, HIV viral 155 suppression, blood pressure) were then included in a multivariable logistic regression model for each of 156 the five equations.

157 Ethical considerations

158 Ethical approval was received from the Uganda Virus Research Institute (UVRI) Research Ethics 159 Committee (reference number GC/127/946), the Uganda National Council of Science and Technology 160 (HS2578ES) and the London School of Hygiene and Tropical Medicine institutional review board 161 (28797). Information about the study appropriate for adults, semi-literate adults and children was 162 provided in an information booklet that was read to the participants and caregivers. All the participants 163 more than 18 years of age provided a written informed consent. Those below 18 years of age provided 164 assent and their caregivers provided written informed consent. If a child refused to provide assent even 165 after their caregiver had provided consent, that child was not enrolled into the study. All participants had 166 the option to withdraw at any point during the research. All participants with suspected CKD were 167 referred to a nephrologist for management.

7

168 **Results**

- 169 Of 532 YPLHIV invited to participate, 500 were enrolled as the 32 declined to participate (**Table 1**). The
- 170 majority were female (56.0%; n=280), children aged 10-17 years (66.9%; n=335) and living in Kampala
- 171 (58.9%; n=295). Females had better nutritional indicators than males they were less likely to be
- 172 underweight (26.4% vs 48.9%; p<0.001), not stunted (85.6% vs 76.9%; p=0.03), and to have normal mid
- 173 upper circumference (92.9% vs 87.7%; p=0.05).

174 Table 1: Demographic characteristics of the study participants by sex.

	Male	Female	Total
	N=220 (44%)	N=280 (56%)	N=500
Age (mean, SD)	16.5 (3.8)	16.3 (3.5)	16.4 (3.6)
Age category			
Children	143 (65.0)	191 (68.2)	334 (66.8)
Adults	77 (35.0)	89 (31.8)	166 (33.2)
Address			
Kampala	123 (55.9)	171 (61.1)	294 (58.8)
Wakiso	80 (36.4)	99 (35.4)	179 (35.8)
Other districts	17 (7.7)	10 (3.6)	27 (5.4)
Religion			
Christian	158 (71.8)	204 (72.9)	362 (72.4)
Moslem	62 (28.2)	73 (26.1)	135 (27.0)
Other	0 (0.0)	3 (1.1)	3 (0.6)
Social Economic Status			
Lowest	78 (35.5)	100 (35.7)	178 (35.6)
Middle	61 (27.7)	94 (33.6)	155 (31.00
Highest	81 (36.8)	86 (30.7)	167 (33.4)
School going			
No	58 (26.4)	67 (23.9)	125 (25.0)
Yes	162 (73.6)	213 (76.1)	375 (75.0)
Marital Status			
Married	3 (1.4)	16 (5.7)	19 (3.80)
Never married	217 (98.6)	264 (94.3)	481 (96.2)
Tribe			
Ganda	149 (67.7)	174 (62.1)	323 (64.6)
Other tribes	65 (29.5)	86 (30.7)	151 (30.2)
Non-Ugandan	6 (2.7)	20 (7.1)	26 (5.2)
Weight mean (SD)	48.0 (12.4)	49.4 (12.4)	48.8 (12.4)
Body Mass Index ¹			

Normal	173 (79.0)	214 (76.4)	387 (77.6)
Underweight (<18.5kg/m ²)	38 (17.3)	24 (8.6)	62 (12.4)
Overweight (>25kg/m ²⁾	8 (3.7)	42 (15.0)	50 (10.0)
Stunting**			
Not stunted	123 (76.9)	184 (85.6)	307 (81.9)
Stunted	37 (23.1)	31 (14.4)	68 (18.3)
Mid Upper Arm			
Circumference ²			
Normal	192 (87.7)	260 (92.9)	452 (90.6)
Malnourished	27 (12.3)	20 (7.1)	47 (9.4)
On TDF regimen			
No	61 (27.7)	66 (23.6)	127 (25.4)
Yes	159 (72.3)	214 (76.4)	373 (74.6)
Virally suppressed			
Yes	195 (89.5)	247 (88.5)	442 (88.9)
No	23 (10.5)	32 (11.5)	55 (11.1)
Muscle mass ²			
Normal muscle mass	164 (82.0)	235 (87.7)	399 (85.3)
Abnormal muscle mass	36 (18.0)	33 (12.3)	69 (14.7)

175 ** Living outside Kampala/Wakiso region. # included those with no religion and those of African traditional religion.*

176 ***Only those aged less than 19 years. 1 one missing, 2. 32 missing as their measurements were below threshold of*

177 *the BIS machine.*

178 Comparison of serum creatinine and cystatin C

179 The mean serum creatinine (scr) was 0.63 mg/dl (SD 0.15) with a range of 0.29 to 1.2mg/dl. The mean scr

180 was significantly different according to sex, age, presence of stunting or viral suppression. The mean

181 cystatin C was 0.81 mg/dl (SD 0.13) with a range of 0.51 to 1.39 mg/dl. The mean cystatin C was higher

in males at 0.86 mg/dl versus 0.78 mg/dl in females but with no other differences (Supplemental table

183 1). Serum creatinine but not cystatin C was correlated with age and sex (**Figure 1**).

184 Figure 1: Relationship between serum creatinine and cystatin C and age for males and females



185

186 **Distribution of the eGFR**

- 187 CKDEPI consistently gave higher eGFR readings for both creatinine and cystatin C, and the Schwartz
- 188 cystatin C equation gave the lowest eGFR values (**Figure 2**).

189 Figure 2. Kernel density plot showing the distribution of the eGFR according to different estimating

190 equations and biomarkers.



192 Scr serum creatinine, CG cockroft Gault, cys Cystatin C

193 Prevalence of CKD using eGFR

- 194 CKD prevalence varied according to the eGFR cut-off, and the biomarker used. Using an
- 195 $eGFR < 60 ml/min/1.73 m^2$ cut-off, the highest prevalence was with the Schwartz cystatin C equation
- 196 (1.4%; 95% CI: 0.5-2.9% at baseline; 0.8%; 95% CI: 0.2-2.1% at 3-month follow-up) and the lowest with
- the CKDEPI 2021 equation (0%; 95% CI 0-0.07%). Similarly, using eGFR< 90ml/min/1.73m² cut-off,
- the highest prevalence was with the Schwartz cystatin C equation (58.9%; 95% CI: 54.4-63.3%) and the
- lowest with CKDEPI (0.6%; 95% CI: 0.01-1.7%) (Figure 3). Prevalence using other eGFR equations
- 200 ranged from 0% to 27.5% (**Supplementary Table 2**).
- Figure 3 Prevalence of CKD according to the different estimating equations and biomarkers.



202

203 Prevalence of CKD according to eGFR and ACR

All participants were staged according to combined baseline eGFR using cystatin C and ACR to assess

risk of progression (28). Overall, 438 (88.5%) participants had low risk of progression (green), 53

206 (10.7%) had intermediate risk of progression (yellow) and 4 (0.8%) were at high risk of progression

207 (orange) (**Table 2**).

Table 2. All participants' CKD status staged according to estimated GFR from cystatin C and albumin creatinine ratio at baseline.

eGFR and ACR c	ategories	ACR categories in mg/g				
		<30 Normal to mildly increased	30-299 Moderately increased	>300 Severely increased	Total numbers	
eGFR	Stage	A1	A2	A3		
>90 Normal and high	G1	178 (36.0%)	24 (4.9%)	1 (0.2%)	203 (41.1%)	
60-89 Mild reduction	G2	258 (52.2%)	24 (4.9%)	2 (0.2%)	284 (57.5%)	
45-59 Mild to moderate reduction	G3a	5 (1.0%)	2 (0.4%)	0 (0%)	7 (1.4%)	
		441 (89.3%)	50 (10.1%)	3 (0.6%)	494* (100%)	

eGFR estimated glomerular filtration rate, ACR Albumin creatinine ratio, *6 participants were missing

211 serum creatinine and cystatin C results.

212 Prevalence of CKD according to markers of kidney damage

- 213 Urinalysis showed that 143 (29%) participants had proteinuria on dipstick. Prevalence of proteinuria was
- similar for those with eGFR>90ml/min/ $1.73m^2$ and <90ml/min/ $1.73m^2$ (24.6% vs 31.7% p=0.17). At
- baseline, 10.1% (50) and at follow up, 3.8% (19) participants had an ACR >30mg/g.

216 Factors associated with CKD.

- Factors associated with CKD varied with the equation and biomarker used for those with an eGFR
- 218 <90ml/min/1.73m² (**Table 3**) but was largely associated with male sex (with the exception of
- 219 CKDEPI2021), viral non-suppression (by the cystatin C based equations), increasing age (by the CKDEPI
- and Bedside Schwartz equations), and being overweight (with the exception of the Cockroft-Gault
- equation). CKD was also associated with proteinuria (by the CKDEPI 2012 equation) and being on a
- 222 TDF-based regimen (by the Bedside Schwartz equation). There was no evidence that CKD was associated
- 223 with high blood pressure, muscle mass, and ACR.
- Results were similar when using CKD defined by eGFR<60ml/min/1.73m² (**Supplementary Table 3**).
- Table 3. Factors associated with having CKD (eGFR<90ml/min/1.73m²) among study participants
- according to the different estimating equations and biomarkers.
- 227 OR Odds ratio ART Anti-retroviral therapy. N Number, eGFR estimated glomerular filtration rate*
- 228 Adjusted for age, sex, blood pressure, viral suppression proteinuria, baseline CD4 T cell count.
- 229 Discussion

230 This is the first study to compare the prevalence and factors associated with CKD diagnosed by creatinine

- and cystatin C among YPLHIV in Uganda according to standard guidelines. We found highly variable
- prevalence depending on the definition, the estimating equation and the biomarker used. This was

233 compounded by the commonly used GFR estimating equations being recommended for adults or children 234 only, despite the highly variable physical and sexual maturity within this important age group where long-235 term disease management is critical. Using cystatin C eGFR measures consistently gave substantially 236 higher prevalence of CKD: using the Schwartz cystatin equation approximately 60% of YPLHIV had eGFR <90mls/min/1.73m². While dipstick proteinuria is anticipated in this population largely treated with 237 238 anti-retroviral drugs, 10% of participants had substantially elevated levels of albuminuria. However, when 239 participants with baseline abnormalities were remeasured at 3 months according to the gold-standard 240 definition, overall prevalence of CKD was much lower. The highest prevalence (59%) using an eGFR cutoff <90ml/min/1.73m² at baseline which fell to 23% at 241

three months follow-up, was very high. This is similar to a study done in 96 Nigerian YPLHIV aged 15 to
29 years which found 53.3% prevalence (36) and a Tanzanian study among 240 YPLHIV aged less than
14 years that showed a prevalence of 28% (37). When kidney function was determined by eGFR below
60ml/min/1.73m² on two separate occasions at least three months apart, the prevalence of CKD was
0.8%. This is lower than in a study done in Zambia among children living with HIV aged 1 to 18 years
that found a prevalence of 3.8% after 3 months (38). However, the children in this study were younger
than in this study.

Using a eGFR cut off of less than 60ml/min/1.73m² excludes a large proportion of YPLHIV who are already showing signs of impaired kidney function such as an ACR above 30mg/g, proteinuria and hypertension, and who would benefit from early intervention to halt progression of their kidney disease (39). Pottel et al. have shown that clinical manifestations of decreased kidney function in young people start at GFR less than 75ml/min/1.73m²; they recommend that the CKD definition should be revised to reflect this (40).

KDIGO recommends that screening and surveillance for CKD be tailored to the specific high risk group
(41). Our study suggests that using sequential estimation of eGFR over three months excludes YPLHIV at
risk of CKD, and might be misleading to the public health response whose goal is to halt progression and

to predict those who are in danger of kidney failure or development of cardiovascular complications (41).
KDIGO further recommends that screening frequency should be based on the risk profile of the individual
and potential to progress (42). YPLHIV have the potential to progress due to the continued insult to the
kidney, one abnormal eGFR measurement that shows reduced kidney function should be sufficient for
them to be followed up regularly and managed.

Estimating GFR in this population was challenging as the different estimating equations and biomarkers 263 264 gave very different results. This was worse as one transitioned from equations meant for those below 18 265 years to those equations meant for adults above 18 years. The difference in the eGFR was wide even in 266 the same individual. It is difficult to determine the true estimate for CKD among YPLHIV using these 267 estimating equations yet knowing the true estimate is important to plan the public health response for 268 CKD (15). Clinicians who seek to diagnose CKD and plan management may get confused about the true 269 CKD status of an individual. Misdiagnosis and classification of YPLHIV removes the opportunity to 270 intervene early to halt progression to kidney failure (43). However, it is not surprising that each of the 271 estimating equations gave a different prevalence since each estimating equation reflects the characteristics 272 of the population/dataset that was used to develop it (44). There is an urgent need to develop estimating 273 equations for Africans living in Africa.

274 The use of GFR alone doesn't predict progression or mortality risk and other markers of kidney damage 275 such as albuminuria or proteinuria are used (13, 45). When ACR was used, the prevalence was 10.1%. 276 This is lower than that reported among a Tanzanian cohort of YPLHIV aged 1 to 14 years which found a 277 prevalence of 20.1% (37). However, the ACR was determined at a single time point and included younger 278 children. Proteinuria prevalence was 29% which was high in such a young population. Proteinuria is an 279 early marker of HIV associated nephropathy (46) and if persistent, is predictive of CKD status in children 280 (47). However, we measured proteinuria only at baseline and yet two positive out of three readings are 281 used to diagnose persistent proteinuria (41).

15

282 Cystatin C emerged as a better biomarker than serum creatinine as eGFR calculated from Cystatin C was 283 above CKD stage 1 more consistently for all those that had an increased ACR, proteinuria or hypertension which are markers of abnormal kidney function (18). Cystatin C was recommended by a recent study in 284 285 three countries (Uganda, Malawi, and South Africa) as the better biomarker in Africans (4). Cystatin C 286 should be recommended for the diagnosis of CKD in YPLHIV as well. 287 We found that age, sex, and HIV viral non-suppression were associated with CKD and that proteinuria, 288 CD4 cell count, blood pressure, and being on a TDF regimen were not associated. A study among 289 perinatally infected YPLHIV in South Africa with a mean age of 12.0 years found sex, but not age or 290 blood pressure were associated with CKD (48). Males were also found to have more CKD than females in

a study in Zimbabwe (49). TDF use was also not associated with CKD status in a cohort of American

children with CKD (50).

293

294 One of the strengths of this study is that we estimated the eGFR at two different time points more than 295 three months apart as recommended by KDIGO and were able to ascertain those that actually had CKD 296 according to the standard definition of CKD. However, most of the GFR estimating equations and normal 297 serum creatinine have not been validated in YPLHIV in resource-limited settings especially in Africa and 298 this makes it that much harder to determine the abnormal values in YPLHIV (4, 51). This could explain 299 the low correlation between eGFR and the markers of kidney damage found in this study. We determined 300 both markers of kidney damage (albuminuria and proteinuria) and function and could tell YPLHIV that 301 were at risk of CKD progression. The biggest limitation is that we did not measure the GFR using either ioxehol or the nuclear tracers 99mTc-diethylenetriaminepentaacetic acid (DTPA) or ⁵¹Cr-EDTA (10) and 302 303 so we are unable to tell how accurate the eGFR was.

304 Conclusion

305 CKD prevalence among YPLHIV in Uganda varies widely depending on the biomarker and definition
 306 used. However, there is a substantial prevalence of albuminuria and reduced eGFR suggesting HIV

16

- 307 programs should prioritize screening for CKD among YPLHIV. The definition of CKD and best
- 308 biomarker to use in YPLHIV should be further investigated to optimise detection of those with early
- 309 abnormalities of kidney function. Estimating equations should be validated against measured GFR in
- 310 young people to define how best to estimate GFR across older children and young adults in Africa.

311 List of abbreviations

ACR	Albumin Creatinine Ratio
AIDS	Acquired Immune Deficiency Syndrome
ALHIV	Adolescents living with HIV
ART	Anti-Retroviral Therapy
BIS	Bioimpedance Spectroscopy
BMI	Body Mass Index
CAKUT	Congenital abnormalities of the Kidney and Urinary Tract
CALHIV	Children and Adolescents living with HIV
CAP	College of American Pathologists
CBC	Complete Blood Count
CD4	Cluster of differentiation 4
CKD	Chronic Kidney Disease
CKD-EPI	Chronic Kidney Disease Epidemiology Collaboration
DM	Diabetes Mellitus
ESKD	End stage kidney disease

- EKFC European Kidney Function Consortium
- FAS Full Age Spectrum
- GFR Glomerular Filtration Rate
- HB Haemoglobin
- HIV Human Immunodeficiency Virus
- HIVAN HIV associated Nephropathy
- HIVICK HIV Immune Complex Kidney Disease
- HW Health Worker
- IQR Interquartile Range
- KDIGO Kidney Disease Improving Global Outcomes
- KRT Kidney replacement therapy
- MDRD Modification of Diet in Renal Disease
- MOH Ministry of Health
- NCD's Non-Communicable Diseases
- PCR Protein Creatinine Ratio
- PLHIV People Living with HIV AIDS
- RAAS Renin Angiotensin Aldosterone Systems
- RCT Randomised Controlled Trials
- SSA Sub Saharan Africa

ТВ	Tuberculosis
UNAIDS	United Nations Joint AIDS program
USA	United States of America
WHO	World Health Organization
YPLHIV	Young People Living with HIV

312

313 Declarations

314 Ethics approval and consent to participate

315 Ethical approval was received from the Uganda Virus Research Institute (UVRI) Research Ethics

Committee (reference number GC/127/946), the Uganda National Council of Science and Technology

317 (HS2578ES) and the London School of Hygiene and Tropical Medicine institutional review board

318 (28797). Information about the study appropriate for adults, semi-literate adults and children was

provided in an information booklet that was read to the participants and caregivers. All the participants

more than 18 years of age provided a written informed consent. Those below 18 years of age provided

321 assent and their caregivers provided written informed consent. If a child refused to provide assent even

322 after their caregiver had provided consent, that child was not enrolled into the study. All participants had

the option to withdraw at any point during the research. All participants with suspected CKD were

324 referred to a nephrologist for management.

325 **Consent for publication:** Not applicable

326 Availability of data and materials

327 The data supporting the findings of this study are openly available in repository

328 https://datacompass.lshtm.ac.uk/.

329 Competing interests

330 The authors declare no conflict of interest.

331 Funding

332 Support for research was provided by Fogarty International Centre, National Institutes of Health (grant

333 #2D43TW009771-06) HIV and co-infections in Uganda. HAW is funded by the UK Medical Research

- 334 Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID
- 335 Concordat agreement (Grant 1: MR/R010161/1). EN, Doctoral Research Fellow, NIHR131273 is funded
- by the NIHR for this research project. The views expressed in this publication are those of the authors and
- not necessarily those of the NIHR, NHS or the UK Department of Health and Social Care.

338 Authors' contributions

EN, LT, RK, CDC, DN, BC, YCM, HW contributed to the conceptualization and design of the study, data

collection, analysis, and interpretation. EN, LT, YK drafted the manuscript. CDC, BC, RK, YCM edited

- 341 the draft manuscript. HW was responsible for the overall supervision of this work. All authors reviewed
- and approved the manuscript before submission for publication.

343 Acknowledgements

The authors acknowledge the health workers and peers at the implementing facilities where this data was collected. The HIV program at the participating health facilities is supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through CDC.

- 347
- 348

349 References

- Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney International
 Supplements. 2022;12(1):7-11.
- 352 2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease:

Evaluation, classification, and stratification. American Journal of Kidney Disease 39:S1–S266. 2002.

Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and
 national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of
 Disease Study 2017. The lancet. 2020;395(10225):709-33.

Fabian J, Kalyesubula R, Mkandawire J, Hansen CH, Nitsch D, Musenge E, et al. Measurement
 of kidney function in Malawi, South Africa, and Uganda: a multicentre cohort study. The Lancet Global
 Health. 2022;10(8):e1159-e69.

5. Fabian J, George JA, Etheredge HR, van Deventer M, Kalyesubula R, Wade AN, et al. Methods
and reporting of kidney function: a systematic review of studies from sub-Saharan Africa. Clinical
Kidney Journal. 2019;12(6):778-87.

363 6. Naicker S, Fabian J. Risk factors for the development of chronic kidney disease with HIV/AIDS.
364 Clin Nephrol. 2010;74 Suppl 1:S51-6.

Frigati LJ, Ameyan W, Cotton MF, Gregson CL, Hoare J, Jao J, et al. Chronic comorbidities in
children and adolescents with perinatally acquired HIV infection in sub-Saharan Africa in the era of
antiretroviral therapy. The Lancet Child & Adolescent Health. 2020;4(9):688-98.

368 8. Jotwani V, Atta MG, Estrella MM. Kidney Disease in HIV: Moving beyond HIV-Associated
369 Nephropathy. Journal of the American Society of Nephrology. 2017;28(11):3142-54.

Kalyesubula R, Wearne N, Semitala FC, Bowa K. HIV-associated renal and genitourinary
 comorbidities in Africa. Journal of acquired immune deficiency syndromes (1999). 2014;67 Suppl 1:S68 78.

Purswani MU, Chernoff MC, Mitchell CD, Seage GR, Zilleruelo G, Abitbol C, et al. Chronic
kidney disease associated with perinatal HIV infection in children and adolescents. Pediatric nephrology.
2012;27(6):981-9.

Bhimma R, Purswani MU, Kala U. Kidney disease in children and adolescents with perinatal
HIV 1 infection. Journal of the International AIDS Society. 2013;16(1):18596.

Innes S, Patel K. Non-communicable diseases in adolescents with perinatally-acquired HIV-1
infection in high-and low-income settings. Current opinion in HIV and AIDS. 2018;13(3):187.

Bunupuradah T, Phupitakphol T, Sophonphan J, Prasitsuebsai W, Anugulruengkitt S,
Jantarabenjakul W, et al. Prevalence of persistent renal dysfunction in perinatally HIV-infected Thai
adolescents. Pediatr Infect Dis J. 2018;37(1):66-70.

Bernheimer JM, Patten G, Makeleni T, Mantangana N, Dumile N, Goemaere E, et al. Paediatric
HIV treatment failure: a silent epidemic. J Int AIDS Soc. 2015;18:20090.

Stanifer JW, Muiru A, Jafar TH, Patel UD. Chronic kidney disease in low-and middle-income
 countries. Nephrology Dialysis Transplantation. 2016;31(6):868-74.

16. Kalyesubula R, Makanga G, Gyagenda JO, Atuhe D, Kansiime G, Kiggundu D, et al. Nephrology
in Uganda. Nephrology Worldwide. 2021:75-83.

389 17. George C, Mogueo A, Okpechi I, Echouffo-Tcheugui JB, Kengne AP. Chronic kidney disease in
390 low-income to middle-income countries: the case for increased screening. BMJ Glob Health.
391 2017;2(2):e000256.

- 18. Lopez-Giacoman S, Madero M. Biomarkers in chronic kidney disease, from kidney function to
 kidney damage. World journal of nephrology. 2015;4(1):57.
- 19. Levey AS, Titan SM, Powe NR, Coresh J, Inker LA. Kidney Disease, Race, and GFR Estimation.
 Clinical Journal of the American Society of Nephrology. 2020;15(8):1203-12.
- 20. Carrara F, Gaspari F. GFR measured by iohexol: the best choice from a laboratory perspective.
 Journal of Laboratory and Precision Medicine. 2018;3.
- 398 21. Kashani K, Rosner MH, Ostermann M. Creatinine: From physiology to clinical application.
 399 European Journal of Internal Medicine. 2020;72:9-14.
- 400 22. Shlipak MG, Mattes MD, Peralta CA. Update on cystatin C: incorporation into clinical practice.
 401 American Journal of Kidney Diseases. 2013;62(3):595-603.

402 23. Seape T, Gounden V, van Deventer HE, Candy GP, George JA. Cystatin C- and creatinine-based
403 equations in the assessment of renal function in HIV-positive patients prior to commencing Highly Active
404 Antiretroviral Therapy. Annals of Clinical Biochemistry. 2016;53(1):58-66.

405 24. Mauss S, Berger F, Kuschak D, Henke J, Hegener P, Wolf E, et al. Cystatin C as a marker of
406 renal function is affected by HIV replication leading to an underestimation of kidney function in HIV
407 patients. SAGE Publications Sage UK: London, England; 2008.

408 25. Mian AN, Schwartz GJ. Measurement and estimation of glomerular filtration rate in children.
409 Advances in chronic kidney disease. 2017;24(6):348-56.

Shlipak MG, Matsushita K, Ärnlöv J, Inker LA, Katz R, Polkinghorne KR, et al. Cystatin C
versus creatinine in determining risk based on kidney function. New England Journal of Medicine.
2013;369(10):932-43.

413 27. Queremel Milani DA, Jialal I. Urinalysis: StatPearls Publishing, Treasure Island (FL); 2020 2020.

Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, De Jong PE, et al. Kidney Disease:
Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for
the evaluation and management of chronic kidney disease. Kidney international supplements.
2013;3(1):1-150.

- 418 29. Levey AS, Eckardt K-U, Dorman NM, Christiansen SL, Cheung M, Jadoul M, et al.
- Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease:
 Improving Global Outcomes (KDIGO) consensus conference. Kidney Diseases. 2020;6(5):309-17.
- ⁴²⁰ Improving Global Galeonies (RD100) consensus conference. Ridney Diseases. 2020,0(5).509 17.
- 30. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New Creatinine- and
 Cvstatin C–Based Equations to Estimate GFR without Race. New England Journal of Medicine.
- 423 2021;385(19):1737-49.

Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to
estimate GFR in children with CKD. Journal of the American Society of Nephrology: JASN.
2009;20(3):629.

32. Schwartz GJ, Schneider MF, Maier PS, Moxey-Mims M, Dharnidharka VR, Warady BA, et al.
Improved equations estimating GFR in children with chronic kidney disease using an
immunonephelometric determination of cystatin C. Kidney International. 2012;82(4):445-53.

430 33. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating
431 glomerular filtration rate from serum creatinine and cystatin C. New England Journal of Medicine.
432 2012;367(1):20-9.

433 34. Levey AS, Coresh J. Chronic kidney disease. The Lancet. 2012;379(9811):165-80.

434 35. Flynn JT, Falkner BE. New Clinical Practice Guideline for the Management of High Blood
435 Pressure in Children and Adolescents. Hypertension (Dallas, Tex : 1979). 2017;70(4):683-6.

36. Okafor UH, Unuigbe EI, Chukwuonye E. Prevalence and clinical and laboratory characteristics of
kidney disease in anti-retroviral-naive human immunodeficiency virus-infected patients in South-South
Nigeria. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center
for Organ Transplantation, Saudi Arabia. 2016;27(1):129-34.

440 37. Fredrick F, Francis JM, Ruggajo PJ, Maro EE. Renal abnormalities among HIV infected children
441 at Muhimbili National Hospital (MNH)-Dar es Salaam, Tanzania. BMC nephrology. 2016;17:30.

38. Zimba KM. Prevalence and factors associated with renal dysfunction in HIV positive paediatric
patients on highly active antiretroviral therapy at the paediatric centre of excellence of the university
teaching hospital, in Lusaka, Zambia. Pediatric Nephrology. 2016;31(10):1778.

445 39. Uhlig K, Johnson CA, Levey AS. New guidelines spell out approach to chronic kidney disease:
446 early diagnosis of chronic kidney disease widens the window of opportunity to put effective treatments to
447 work. Recent National Kidney Foundation clinical practice guidelines provide a simple definition, a
448 practical staging system, and a stage-appropriate action plan. Patient Care. 2003;37(7):38-45.

449 40. Pottel H, Hoste L, Delanaye P. Abnormal glomerular filtration rate in children, adolescents and
450 young adults starts below 75 mL/min/1.73 m 2. Pediatric Nephrology. 2015;30:821-8.

41. Levey A, Atkins R, Coresh J, Cohen E, Collins A, Eckardt K-U, et al. Chronic kidney disease as
a global public health problem: approaches and initiatives–a position statement from Kidney Disease
Improving Global Outcomes. Kidney international. 2007;72(3):247-59.

42. Shlipak MG, Tummalapalli SL, Boulware LE, Grams ME, Ix JH, Jha V, et al. The case for early
identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving
Global Outcomes (KDIGO) Controversies Conference. Kidney international. 2021;99(1):34-47.

43. Bhimma R. HIV-Related Kidney Diseases. In: Bobat R, editor. HIV Infection in Children and
Adolescents. Cham: Springer International Publishing; 2020. p. 143-52.

44. Miller WG. Perspective on New Equations for Estimating Glomerular Filtration Rate. Clinical
Chemistry. 2021;67(6):820-2.

- 461 45. Bökenkamp A. Proteinuria—take a closer look! Pediatric Nephrology. 2020;35(4):533-41.
- 462 46. Palau L, Menez S, Rodriguez-Sanchez J, Novick T, Delsante M, McMahon BA, et al. HIVassociated nephropathy: links, risks and management. HIV AIDS (Auckl). 2018;10:73-81. 463
- Beng H, Rakhmanina N, Moudgil A, Tuchman S, Ahn S-Y, Griffith C, et al. HIV-associated 464 47. 465 CKDs in children and adolescents. Kidney international reports. 2020;5(12):2292-300.
- 466 48. Frigati L, Mahtab S, Nourse P, Ray P, Perrazzo S, Machemedze T, et al. Prevalence of risk factors for chronic kidney disease in South African youth with perinatally acquired HIV. Pediatric 467 468 nephrology (Berlin, Germany). 2018;34(2):313-8.
- 469 49. Byers BW, Drak D, Shamu T, Chimbetete C, Dahwa R, Gracey DM. Assessing renal impairment 470 in treatment-naïve adolescents living with HIV commencing antiretroviral therapy in Zimbabwe. AIDS. 471 2023;37(5):789-94.
- 472 50. Purswani M, Patel K, Kopp JB, Seage GR, 3rd, Chernoff MC, Hazra R, et al. Tenofovir treatment
- 473 duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with
- 474 perinatal HIV-1 infection. Pediatr Infect Dis J. 2013;32(5):495-500.
- 51. 475 Swanepoel CR, Atta MG, D'Agati VD, Estrella MM, Fogo AB, Naicker S, et al. Kidney disease
- 476 in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney international. 2018;93(3):545-59.
- 477

478

	eGFR<90ml/min/1.73m2 from Cystatin C based Equations				eGFR<90ml/min/1.73m ² from Serum Creatinine Based Equations					
	CKD EPI 2012 (n=36/494)		Schwartz (n=29	z Cystatin 91/494)	CKDE (n=6	PI 2021 /494)	Bedside S (n=140	Schwartz 0/494)	Cockro (n=68	ft Gault 3/493)
	Unadjusted OR	Adjusted OR*	Unadjusted OR	Adjusted OR	Unadjusted OR	Adjusted OR	Unadjusted OR	Adjusted OR	Unadjusted OR	Adjusted OR
Age in years	1.14	1.13	0.98	0.99	1.50	1.45	1.40	1.42	0.99	1.08
	(1.03-1.25)	(1.01-1.27)	(0.94-1.04)	(0.94-1.04)	(1.13-1.98)	(1.01-2.14)	(1.30-1.51)	(1.28-1.58)	(0.94-1.04)	(0.96-1.22)
Age categorized	1									
>18	1	1	1		1		1		1	
<18	0.47		1.06		0.09		0.17		0.89	0.63
	(0.33 - 0.92)		(0.73 - 1.55)		(0.01 - 0.83)		(0.11 - 0.26)		(0.52 - 1.52)	(0.23 - 1.77)
Sex										
Females	1		1		1		1		1	
Males	2.42	2.84	3.21	3.13	0.64	0.75	2.22	3.02	3.21	0.32
	(1.2-4.92)	(1.27-6.31)	(2.18-4.71)	(2.12-4.65)	(0.12-3.52)	(0.11-4.92)	(1.49-3.32)	(1.68-5.43)	(2.18-4.71)	(0.16-0.60)
Blood pressure										
Normal	1	1	1		1	1	1	1	1	1
Elevated	0.59	0.41	1.69	1.42	0.07	0.35 ()	1.19	1.02	0.41	0.26
	(0.17-1.98)	(0.86-1.90)	(0.95-2.98)	(0.79-2.59)	(0.00-0.63)		(0.66-2.17)	(0.45-2.31)	(0.21-0.78)	(0.08-0.80)
Hypertensive	0.98	0.69	1.25	1.14	0.45	1.61	2.42	1.69	0.73	0.58
	(0.39-2.45)	(0.26-1.89)	(0.76-2.06)	(0.67-1.94)	(0.04-4.04)	(0.24,10.63)	(1.46-4.02)	(0.89-3.29)	(0.35-1.50)	(0.18-1.86)
Viral suppressi	on									
Suppressed	1	1	1	1	1		1		1	
Non	3.11	3.27	2.09	2.29	1.01	0.92 (.,.)	0.42	0.34	0.63	0.61
suppressed	(1.38-7.04)	(1.29-8.32)	(1.11-3.97)	(1.18-4.44)	(0.00-7.12)		(0.19-0.91)	(0.13-0.89)	(0.24-1.64)	(0.21-1.74)
CD4 T cell cou	nt at baseline									
>500	1	1	1		1		1		1	
200-500	2.3	1.41	1.54		1.52		1.86	0.66	1.08	
	(0.98-5.38)	(0.55-3.59)	(0.96-2.48)		(0.03-29.58)		(1.03-3.04)	(0.35-1.25)	(0.56-2.10)	
<200	3.84	2.59	1.76		5.34		1.89	0.65	1.22	
	(1.5-9.38)	(0.97-6.92)	(0.96-3.22)		(0.38-75.78)		(1.04-3.46)	(0.29-1.44)	(0.56-2.68)	
Social Economi	c Status									
Least	1		1		1		1		1	
Middle	1.03		0.96		2.28		1.34	1.32	1.04	
	(0.42 - 2.49)		(0.62 - 1.49)		(0.81 - 2.21)		(0.62 - 1.49)	(0.69-2.51)	(0.56 - 1.92)	

Highest	1.47		1.15	1.85	1.15	1.40	0.81					
8	(0.66-3.31)		(0.74-1.78)	(1.15-2.99)	(0.75-1.78)	(0.75-2.64)	(0.43-1.52)					
Body Mass Inde	Body Mass Index											
Normal	1		1	1	1		1	1				
Underweight	1.69		1.36	0.29	0.31	0.74	4.03	7.23				
	(0.82-3.43)		(0.92-2.01)	(0.00-2.30)	(0.18-0.51)	(0.32-1.68)	(2.29-7.09)	(3.33-15.7)				
Overweight	1.27		1.24	3.11	1.81	1.98	0.19					
	(0.35-4.56)		(0.63-2.43)	(0.27-22.51)	(0.94-3.51)	(0.68-5.74)	(0.00-1.12)					
Weight in Kg	1.02		1.01	-	1.06	0.99						
	(0.99-1.04)		(0.99-1.02)		(1.04-1.09)	(0.96-1.04)						
Stunting												
Not stunted	1		1	1	1		1					
Stunted	1.42		0.88	-	0.67		1.81					
	(0.50-4.02)		(0.52-1.51)		(0.31-1.43)		(0.87-3.73)					
Mid Upper Arm Circumference												
Normal	1		1	1	1		1					
Malnourished	1.64		0.74	-	0.43	0.82	4.05	1.81				
	(0.60-4.44)		(0.40-1.36)		(0.18-0.98)	(0.29-2.39)	(2.07-7.93)	(0.79-4.13)				
Muscle mass												
Normal	1		1	1	1		1					
Abnormal	1.10		1.28	3.89	1.44		0.96					
	(0.41-2.98)		(0.76-2.18)	(0.64-23.66)	(0.84-2.48)		(0.45-2.05)					
Proteinuria												
Negative	1		1	1	1		1					
Positive	3.40	3.71	1.44	1.22	1.49		1.12					
	(1.7-6.78)	(1.75-7.88)	(0.96-2.15)	(0.11-8.69)	(0.98-2.27)		(0.64-1.95)					
Albumin creati	nine ratio											
<30	1		1									
>30	1.74		0.76	1.67	0.89							
	(0, c0, 1, 1)		(0 10 1 0 1)	(0.19-14.6)	(0.47 - 1.71)							
On Tenofovir based regimen												
On Tenofovir b	(0.69-4.4) based regimen		(0.43-1.34)	(0.17 11.0)	(0.47-1.71)							
On Tenofovir b No	(0.69-4.4) pased regimen 1		(0.43-1.34)	1	1		1					
On Tenofovir b No Yes	(0.69-4.4) pased regimen 1 1.45		(0.43-1.34)	1 1.72	1 3.22	1.87	1 0.63					
On Tenofovir b No Yes	(0.69-4.4) pased regimen 1 1.45 (0.62-3.41)		(0.43-1.34) <u>1</u> 0.97 (0.64-1.46)	1 1.72 (0.19-14.88)	1 3.22 (1.85-5.61)	1.87 (0.94-3.73)	1 0.63 (0.36-1.08)					
On Tenofovir b No Yes Duration on AF	(0.69-4.4) pased regimen 1 1.45 (0.62-3.41) RT in years		(0.43-1.34) 1 0.97 (0.64-1.46)	1 1.72 (0.19-14.88)	(0.47-1.71) 1 3.22 (1.85-5.61)	1.87 (0.94-3.73)	1 0.63 (0.36-1.08)					

6 to 10	0.49	0.79	0.75 (-,-)	0.92	0.78	
	(0.17-1.43)	(0.46-1.39)		(0.49-1.71)	(0.37-1.61)	
>10	1.11	1.12	1.27 (-,-)	1.31	0.62	
	(0.43-2.89)	(0.64-1.98)		(0.71-2.42)	(0.11-0.39)	





